Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, molecular diagnostic specialist Myriad Genetics (Nasdaq: MYGN ) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Myriad's business and see what CAPS investors are saying about the stock right now.
||Salt Lake City (1991)
||CEO Dr. Peter Meldrum (since 1991)
CFO James Evans (since 2007)
|Return on Equity (average, past 3 years)
||$337.4 million / $0
Siemens Healthcare Diagnostics
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 87% of the 598 members who have rated Myriad believe the stock will outperform the S&P 500 going forward.
Last month, one of those Fools, SharpNJ104, succinctly summed up the Myriad bull case for our community:
Great product[s] without the downside risks of drugs. Increasing contracts with other drug companies for use of their genetic tests for the drug co's drug trials. The future of medicine is personalized based on each inidividual.
If you want market-thumping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its five-star rating, Myriad may not be your top choice.
We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.